HonorHealth

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

Qventus, Inc. is a technology company that develops an artificial intelligence-based software platform aimed at enhancing hospital operations through real-time data analytics. Founded in 2011 and headquartered in Los Altos, California, Qventus provides AI-powered automation solutions that streamline various aspects of healthcare delivery, such as emergency departments, operating rooms, and patient safety. The platform is designed to predict operational challenges, offer immediate recommendations, and prompt healthcare teams to take action, ultimately improving patient flow and resource utilization. By reducing staff workloads and optimizing processes, Qventus enables healthcare organizations to increase capacity and drive revenue while making informed operational decisions in real-time. The company was formerly known as analyticsMD, Inc. before rebranding in March 2017.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

CenSyn develops a portable brain health assessment platform. It comprises a handheld EEG device for rapid neurological evaluation, a mobile app for real-time data viewing, and machine learning algorithms to detect mental status changes. This enables medical professionals to conduct cognitive assessments across various settings.

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

NeoLight, LLC is a medical device company based in Scottsdale, Arizona, that specializes in designing equipment aimed at preventing common infant medical conditions such as jaundice and hypothermia. Incorporated in 2014, NeoLight develops and markets its Skylife phototherapy beds, which deliver effective treatment for jaundice in both pre-term and full-term infants. In addition to its phototherapy solutions, the company also offers devices for hypothermia treatment, specifically targeting infants with low birth weight. Through its innovative products, NeoLight aims to enhance neonatal care and improve health outcomes for vulnerable newborns.